A team using data from two clinical studies found that intrathecal injections of mesenchymal stem cell–neural progenitors (MSC‑NP) changed levels of four cerebrospinal fluid biomarkers, suggesting measurable biological effects of the therapy in people with primary or secondary progressive multiple sclerosis.
CSF levels of four molecules (CCL2, SCF, CHIT1, MMP9) changed consistently after repeated intrathecal MSC‑NP injections across two clinical studies.
Proinflammatory markers CCL2 and SCF decreased after treatment while CHIT1 and MMP9, associated with early repair processes, increased in CSF.
Biomarker changes were observed in cerebrospinal fluid but not in blood, indicating a CNS‑localized biological response to MSC‑NP.
# Study finds four CSF biomarkers change after intrathecal MSC‑NP in progressive MS
Progressive MS subtypes have persistent worsening of symptoms with fewer clear treatment benchmarks. Objective, measurable biomarkers tied to a candidate therapy can show whether the treatment produces a biological effect in the central nervous system (CNS). The team used CSF measurements to look for MSC‑NP–specific changes that might guide future trials.
The investigators measured molecular markers in CSF and blood before and after treatment to identify consistent alterations linked to MSC‑NP.
The researchers characterize the four biomarkers as an identifiable CSF response signature to intrathecal MSC‑NP. They suggest these markers could define biological responses to MSC‑NP and help design future clinical studies, but they also note that links to clinical outcomes remain unclear.
For researchers designing MSC‑NP trials, the CSF biomarker panel offers a way to monitor CNS biological activity of the therapy. Because changes were absent in blood, relying on blood biomarkers would miss these CNS‑specific signals. For clinicians and patients, the findings signal that MSC‑NP can induce measurable molecular changes in the CSF, but evidence that those changes translate into clinical improvement is not established by these data.
The study indicates a need for further research to validate the biomarker panel in independent cohorts, to test whether biomarker shifts predict clinical benefit, and to better understand the biological roles of CHIT1 and MMP9 increases in the context of MSC‑NP treatment.
A new experimental cell therapy that pairs a patient’s own red blood cells with myelin protein fragments safely calmed the immune system and helped dampen the inflammatory attack that drives multiple sclerosis (MS), according to results from an early-stage clinical trial. The novel approach works by retraining the body
The U.S. Food and Drug Administration (FDA) has given Abelzeta Pharma the go-ahead to launch an early-stage clinical trial to test its CAR T-cell therapy candidate for multiple sclerosis (MS) in people with hard-to-treat, progressive forms of the disease. According to Abelzeta, the study’s first part will enroll as man
First generation stem cell therapies have become widespread; they are readily accessed in medical tourism clinics, and are also available for a range of issues in more regulated parts of the world. Initially it was hoped that transplanted cells would engraft and survive to assist tissues in repair and regeneration, but
An experimental therapy called kamuvudine-9 (K-9) reversed established paralysis and vision loss in a mouse model of multiple sclerosis (MS), offering hope for treatments that can restore lost function rather than just prevent future damage. “Most MS therapies are aimed at preventing the next attack. What’s remarkable
Many years ago I dipped my toes into the stem cell World of control and it must have been an ice bath or acid as I lost my toes. At the time there was a lot of interest in mesenchymal stem cells in EAE and MS. The data in EAE was really very weak and […]
Loading more related stories...
Open the app view to save this story, compare related coverage, and continue from the same source.